Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology and pharmaceutical company focused on therapies for pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, and other serious conditions, as well as technologies to expand the availability of transplantable organs. This news page aggregates company announcements, clinical updates, financial disclosures, and conference presentations related to UTHR.
Recent news highlights include detailed results from the TETON-2 phase 3 study of nebulized Tyvaso (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis, where United Therapeutics reported that the trial met its primary efficacy endpoint and achieved statistically significant improvements in several secondary endpoints. The company has also announced the first clinical xenotransplantation of its investigational UKidney xenokidney in the EXPAND study for patients with end-stage renal disease, reflecting its stated public benefit purpose of expanding access to transplantable organs.
Investors and followers of UTHR can review press releases on quarterly financial results, including product-level revenue disclosures for Tyvaso DPI, nebulized Tyvaso, Remodulin, Orenitram, Unituxin, Adcirca, and other items. Additional updates cover accelerated share repurchase agreements, stock incentive plan changes, and participation in major investor conferences hosted by firms such as J.P. Morgan, UBS, Jefferies, and Bernstein.
For those tracking developments in pulmonary hypertension, interstitial lung disease, xenotransplantation, and the company’s public benefit corporation activities, this news feed offers a centralized view of United Therapeutics’ clinical data presentations, regulatory milestones, and corporate actions. Bookmark this page to quickly access new UTHR press releases and related market-moving information as they are published.
United Therapeutics (Nasdaq: UTHR) reported that the TETON-1 pivotal study of nebulized Tyvaso (treprostinil) met its primary endpoint, showing superiority vs placebo with an absolute FVC change of +130.1 mL at week 52 (H-L estimate; 95% CI 82.2–178.1; p <0.0001).
Integrated TETON-1/TETON-2 analyses showed a +111.8 mL FVC benefit (95% CI 79.7–144.0; p <0.0001), reduced risk of clinical worsening, benefits across subgroups, and a plan to seek priority review of a supplemental NDA by the end of this summer.
United Therapeutics (Nasdaq: UTHR) reported full Phase 3 TETON-2 results showing nebulized Tyvaso met the primary endpoint in idiopathic pulmonary fibrosis (IPF).
At week 52, mean absolute FVC change was −49.9 mL for Tyvaso versus −136.4 mL for placebo (between-group difference 95.6 mL; P<0.001); clinical worsening risk fell 29% (HR 0.71; P=0.02). Study enrolled 597 patients; 75.4% were on background antifibrotic therapy. No new safety signals observed. United Therapeutics plans an sNDA filing in the second half of 2026.
United Therapeutics (Nasdaq: UTHR) authorized a $2.0 billion share repurchase program and entered into $1.5 billion of Accelerated Share Repurchase (ASR) agreements with Citibank, comprising $750 million uncollared and $750 million collared ASRs.
The company will make an upfront payment of $1.5 billion on or around March 11, 2026 and receive initial share deliveries (about 70% of uncollared and 50% of collared amounts), with final settlements expected in Q2 and Q3 2026.
United Therapeutics (Nasdaq: UTHR) will present a company overview at the Leerink Global Healthcare Conference on Monday, March 9, 2026, from 1:00–1:30 p.m. EDT. Dr. Martine Rothblatt, Chairperson and CEO, will deliver the presentation.
The session will be available via live webcast on the company's investor site and an archived recording will be posted about 24 hours later and accessible for 90 days.
United Therapeutics (Nasdaq: UTHR) reported that the phase 3 ADVANCE OUTCOMES study of ralinepag met its primary endpoint, reducing risk of clinical worsening by 55% versus placebo (HR 0.45, 95% CI 0.33–0.62; p<0.0001).
Secondary benefits included a 47% increase in odds of clinical improvement (Week 28; p=0.015). United Therapeutics plans an NDA submission by H2 2026 and held a webcast March 2, 2026.
United Therapeutics (Nasdaq: UTHR) reported record full year 2025 revenue of $3.18 billion, up 11% versus 2024, and net income of $1.33 billion. Fourth-quarter revenue was $790.2 million and net income was $364.3 million. Tyvaso revenues and Tyvaso DPI volume rose materially in 2025.
The company cited continued commercial uptake, IRA Part D changes supporting utilization, higher R&D investment, a $21.7 million PP&E impairment, and litigation accruals recorded in the year.
United Therapeutics (Nasdaq: UTHR) will present a company overview at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 from 2:30–3:00 p.m. EST. Michael Benkowitz, President and COO, will deliver the presentation.
The session will be available via live webcast on the company website and an archived recording will be posted about 24 hours later and available for 90 days.
United Therapeutics (Nasdaq: UTHR) will report fourth quarter and full year 2025 financial results before the market opens on Wednesday, February 25, 2026.
A press release will be issued at approximately 6:30 a.m. ET, followed by a public webcast at 9:00 a.m. ET accessible at https://ir.unither.com/events-and-presentations. A rebroadcast will be available for one year at the same location.
United Therapeutics (Nasdaq: UTHR) announced positive Phase 1 results for miroliverELAP, an external bioengineered liver developed by Miromatrix Medical. In a single-arm safety study, five acute liver failure (ALF) patients who were not transplant candidates were treated continuously for at least 44 hours; the trial met its primary endpoint of survival during treatment and reported no unexpected serious adverse events attributable to the device through 32 days of follow-up. The company will initiate a Phase 2 study and full results will be presented and published in the second half of 2026. miroliverELAP is investigational and not approved for any use.
United Therapeutics (Nasdaq: UTHR) announced the appointment of Kevin J. Tracey, M.D. to its Board of Directors effective January 21, 2026. Dr. Tracey serves as President and CEO of The Feinstein Institutes for Medical Research, Professor of Molecular Medicine and Neurosurgery, and Executive VP, Research at Northwell Health.
He is known for research in inflammation and bioelectronic medicine, discovery of neural circuits controlling immunity, work on monoclonal anti-TNF antibodies, multiple patents, and co-founding biotech companies including SetPoint Medical. United Therapeutics said Dr. Tracey will support its therapeutic pipeline for rare pulmonary diseases and organ manufacturing programs, aligning with the company’s public benefit mission.